| |
| |
|
| Insider
Information: |
Townsend Adam J. |
| Relationship: |
Chief Commercial Officer |
| City: |
Crestwood |
| State: |
KY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
92,453 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,855,290 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
92,453 |
|
|
| Total
Value |
$3,855,290 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Apellis Pharmaceuticals Inc |
APLS |
Chief Commercial Officer |
2024-02-12 |
92,453 |
2020-02-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2023-12-01 |
4 |
AS |
$60.50 |
$6,689,303 |
D/D |
(110,000) |
76,407 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2023-12-01 |
4 |
OE |
$15.09 |
$1,659,900 |
D/D |
110,000 |
186,407 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2023-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
27,488 |
70,395 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
26,051 |
45,708 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
23,748 |
100,155 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-08 |
4 |
AS |
$65.00 |
$812,500 |
D/D |
(12,500) |
42,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-08 |
4 |
OE |
$15.09 |
$188,625 |
D/D |
12,500 |
55,407 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-11 |
4 |
AS |
$67.00 |
$837,500 |
D/D |
(12,500) |
42,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-11 |
4 |
OE |
$15.09 |
$188,625 |
D/D |
12,500 |
55,407 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-15 |
4 |
OE |
$15.09 |
$188,625 |
D/D |
12,500 |
55,407 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-15 |
4 |
AS |
$69.00 |
$862,500 |
D/D |
(12,500) |
42,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• – – |
2023-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,886 |
77,036 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
See Remarks |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
9,375 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2021-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,375 |
19,553 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-07-11 |
4 |
OE |
$15.09 |
$75,450 |
D/D |
5,000 |
47,907 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-07-11 |
4 |
AS |
$48.42 |
$242,100 |
D/D |
(5,000) |
42,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-03 |
4 |
AS |
$56.43 |
$282,150 |
D/D |
(5,000) |
37,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-08-03 |
4 |
OE |
$15.09 |
$75,450 |
D/D |
5,000 |
42,907 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-09-06 |
4 |
OE |
$15.09 |
$75,450 |
D/D |
5,000 |
47,907 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-09-06 |
4 |
AS |
$60.38 |
$301,900 |
D/D |
(5,000) |
42,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-10-03 |
4 |
OE |
$15.09 |
$75,450 |
D/D |
5,000 |
47,907 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• • – |
2022-10-03 |
4 |
AS |
$66.69 |
$333,450 |
D/D |
(5,000) |
42,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• – – |
2022-11-03 |
4 |
OE |
$15.09 |
$75,450 |
D/D |
5,000 |
47,907 |
0 |
- |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• – – |
2022-11-03 |
4 |
AS |
$58.54 |
$292,700 |
D/D |
(5,000) |
42,907 |
0 |
% |
|
| APLS |
Apellis Pharmaceuticals I... |
Chief Commercial Officer |
• – – |
2022-12-05 |
4 |
AS |
$50.38 |
$251,900 |
D/D |
(5,000) |
42,907 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
